Tuesday, August 8, 2023 Daily Archives

Fina selects Scorpius to manufacture conjugate vaccine protein

by

Fina Biosolutions has picked Scorpius BioManufacturing to produce an E.coli-expressed CRM197, which is used in conjugate vaccines. Under the terms of the deal, of which financial details have not been disclosed, contract development manufacturing organization (CDMO) Scorpius will manufacture an E.coli-expressed CRM197 conjugate vaccine carrier protein for FinaBio. CRM197 is a genetically detoxified diphtheria toxin, which has been manufactured in the same bacteria that creates the diphtheria toxin used for the diphtheria vaccine. “FinaBio is the first to make it…

August 8, 2023

Kyverna CAR-T pipeline boosted by $145m funding

by

Backed by new investors, Kyverna Therapeutics has extended its Series B funding round to support clinical development of its CAR-T therapies.   Kyverna, a clinical-stage therapy firm focused on producing therapies for autoimmune diseases, has closed a $60 million Series B financing round extension, bringing the total of this round to $145 million. Kyverna closed the first round of its Series B funding in January 2022. Existing investors have been joined by Bain Capital Life Sciences and GordonMD Global Investments. “Kyverna’s…

August 8, 2023